StockData
Immunic, Inc. logo

Immunic, Inc. (IMUX) stock

IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$7.33+0.10 (+1.38%)

Close on Nov 17, 2026Market cap $100.01MP/E –Yield 0.00%

Immunic r&d expenses

Research and development expenses are spending on new products and technology.

Immunic's R&D Expenses for the twelve months ending Jun 30, 2026 was $90.64M, up 5.5% year over year. For fiscal 2025 it was $81.98M, up 2.4% from the year before. Over ten years it grew 7.5% a year on average. The highest annual figure on record is $83.22M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$81.98M+2.4%
FY2024Dec 31, 2024$80.05M-3.8%
FY2023Dec 31, 2023$83.22M+16.8%
FY2022Dec 31, 2022$71.26M+16.6%
FY2021Dec 31, 2021$61.12M+58.2%
FY2020Dec 31, 2020$38.64M+71.6%
FY2019Dec 31, 2019$22.51M+134.6%
FY2018Dec 31, 2018$9.60M-75.6%
FY2017Dec 31, 2017$39.34M+30.9%
FY2016Dec 31, 2016$30.05M-24.5%
FY2015Dec 31, 2015$39.77M+0.7%
FY2014Dec 31, 2014$39.48M+81.2%
FY2013Dec 31, 2013$21.79M+327.4%
FY2012Dec 31, 2012$5.10M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$25.93M+21.3%
Q1 FY2026Mar 31, 2026$25.63M+19.0%
Q4 FY2025Dec 31, 2025$19.07M-11.8%
Q3 FY2025Sep 30, 2025$20.01M-6.4%
Q2 FY2025Jun 30, 2025$21.37M+16.6%
Q1 FY2025Mar 31, 2025$21.53M+14.9%
Q4 FY2024Dec 31, 2024$21.62M+12.1%
Q3 FY2024Sep 30, 2024$21.37M+8.0%
Q2 FY2024Jun 30, 2024$18.32M-13.5%
Q1 FY2024Mar 31, 2024$18.74M-18.4%
Q4 FY2023Dec 31, 2023$19.28M-7.0%
Q3 FY2023Sep 30, 2023$19.80M+19.7%
Q2 FY2023Jun 30, 2023$21.17M+28.0%
Q1 FY2023Mar 31, 2023$22.96M+31.6%
Q4 FY2022Dec 31, 2022$20.74M+12.8%
Q3 FY2022Sep 30, 2022$16.54M+6.8%
Q2 FY2022Jun 30, 2022$16.54M+5.1%
Q1 FY2022Mar 31, 2022$17.45M+51.4%
Q4 FY2021Dec 31, 2021$18.38M+64.4%
Q3 FY2021Sep 30, 2021$15.48M+40.2%
Q2 FY2021Jun 30, 2021$15.74M+57.6%
Q1 FY2021Mar 31, 2021$11.52M+79.0%
Q4 FY2020Dec 31, 2020$11.18M+85.5%
Q3 FY2020Sep 30, 2020$11.04M+55.4%
Q2 FY2020Jun 30, 2020$9.99M+65.6%
Q1 FY2020Mar 31, 2020$6.43M+91.8%
Q4 FY2019Dec 31, 2019$6.03M+42.0%
Q3 FY2019Sep 30, 2019$7.10M+403.7%
Q2 FY2019Jun 30, 2019$6.03M+179.5%
Q1 FY2019Mar 31, 2019$3.36M-67.0%
Q4 FY2018Dec 31, 2018$4.25M-58.3%
Q3 FY2018Sep 30, 2018$1.41M-85.4%
Q2 FY2018Jun 30, 2018$2.16M-78.1%
Q1 FY2018Mar 31, 2018$10.16M+5.5%
Q4 FY2017Dec 31, 2017$10.19M+15.0%
Q3 FY2017Sep 30, 2017$9.69M+29.7%
Q2 FY2017Jun 30, 2017$9.83M–
Q1 FY2017Mar 31, 2017$9.63M–
Q4 FY2016Dec 31, 2016$8.86M–
Q3 FY2016Sep 30, 2016$7.47M–

More Immunic figures

See a number that looks wrong?